A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorInnovent Biologics (Suzhou) Co. Ltd.
About this trial
The purpose of this study is to evaluate how well IBI3003 works when compared with the investigator's choice regimen (DPd or PVd)
Eligibility criteria
Qualifiers
Age ≥18 years.
Documented initial diagnosis of multiple myeloma according to IMWG diagnostic criteria.
Serum M-protein ≥ 5 g/L（For IgA and IgD subtypes, it is recommended to use quantitative immunoglobulin measurements instead of M protein）
Urine M-protein ≥200 mg/24h
Disqualifiers
Previous treatment with any BCMA-targeted therapy and any GPRC5D-targeted therapy. Patients who have received either BCMA-targeted or GPRC5D-targeted therapy are allowed to participate in the study.
Known active CNS involvement or exhibits clinical signs of meningeal involvement of multiple myeloma.
Spinal cord compression that leads to limited self-care ability occurs within six months prior to informed consent or is expected to occur in the near future.
Have history of primary immunodeficiency.
Trial design
Treatments tested in this trial
- Pomalidomide Capsules
- Bortezomib for Injection
- Daratumumab Injection (Subcutaneous Injection)
- IBI3003
Treatment groups
255 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov